financetom
Business
financetom
/
Business
/
Salesforce Insider Sold Shares Worth $1,150,243, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce Insider Sold Shares Worth $1,150,243, According to a Recent SEC Filing
Apr 24, 2024 3:04 PM

05:27 PM EDT, 04/24/2024 (MT Newswires) -- Parker Harris, Director, Co-Founder and CTO, Slack, on April 23, 2024, sold 4,200 shares in Salesforce ( CRM ) for $1,150,243. Following the Form 4 filing with the SEC, Harris has control over a total of 977,253 shares of the company, with 115,762 shares held directly and 861,491 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1108524/000112760224013340/xslF345X03/form4.xml

Price: 273.27, Change: -2.92, Percent Change: -1.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--MDU Ups Quarterly Dividend to $0.13/Share From $0.125, Payable Oct. 1 to Holders of Record on Sept. 12
--MDU Ups Quarterly Dividend to $0.13/Share From $0.125, Payable Oct. 1 to Holders of Record on Sept. 12
Aug 15, 2024
04:57 PM EDT, 08/15/2024 (MT Newswires) -- Price: 25.52, Change: +1.22, Percent Change: +5.02 ...
Alvotech H1 Loss Widens, Revenue Increases; Full-Year Guidance Reaffirmed
Alvotech H1 Loss Widens, Revenue Increases; Full-Year Guidance Reaffirmed
Aug 15, 2024
04:56 PM EDT, 08/15/2024 (MT Newswires) -- Alvotech ( ALVO ) reported an H1 loss late Thursday of $0.61 per diluted share, widening from a loss of $0.39 a year earlier. Revenue for the six months ended June 30 was about $235.6 million, compared with $20.3 million a year earlier. Analysts' estimates were unavailable for comparison. Alvotech ( ALVO )...
Incyte Cancer Treatment Candidate Meets Primary Goal in Study
Incyte Cancer Treatment Candidate Meets Primary Goal in Study
Aug 15, 2024
04:55 PM EDT, 08/15/2024 (MT Newswires) -- Incyte ( INCY ) said Thursday that its cancer drug Monjuvi met the primary goal of phase 3 study by showing progression-free survival in patients with relapsed or refractory follicular lymphoma. Incyte ( INCY ) was evaluating Monjuvi, or tafasitamab, in combination with lenalidomide and rituximab in the study, according to the company....
North Dakota oil production falls for second straight month in June
North Dakota oil production falls for second straight month in June
Aug 15, 2024
Aug 15 (Reuters) - North Dakota's oil production fell by 22,500 barrels per day (bpd) in June to an estimated 1.176 million bpd, the state's Pipeline Authority said on Thursday, marking a second straight monthly decline. Production in the third top oil-producing U.S. state has slipped since climbing to 1.29 million bpd last September, according to figures from its Pipeline...
Copyright 2023-2026 - www.financetom.com All Rights Reserved